- Home
- ASPI vs IVVD Comparison
ASPI vs IVVD Comparison
Compare ASPI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- IVVD
- Stock Information
- Founded
- ASPI 2021
- IVVD 2020
- Country
- ASPI United States
- IVVD United States
- Employees
- ASPI N/A
- IVVD N/A
- Industry
- ASPI Major Chemicals
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- IVVD Health Care
- Exchange
- ASPI Nasdaq
- IVVD Nasdaq
- Market Cap
- ASPI 653.4M
- IVVD 692.7M
- IPO Year
- ASPI 2022
- IVVD 2021
- Fundamental
- Price
- ASPI $5.91
- IVVD $2.26
- Analyst Decision
- ASPI Strong Buy
- IVVD Strong Buy
- Analyst Count
- ASPI 1
- IVVD 4
- Target Price
- ASPI $11.00
- IVVD $8.33
- AVG Volume (30 Days)
- ASPI 7.3M
- IVVD 11.9M
- Earning Date
- ASPI 11-19-2025
- IVVD 11-06-2025
- Dividend Yield
- ASPI N/A
- IVVD N/A
- EPS Growth
- ASPI N/A
- IVVD N/A
- EPS
- ASPI N/A
- IVVD N/A
- Revenue
- ASPI $8,383,354.00
- IVVD $50,039,000.00
- Revenue This Year
- ASPI $264.27
- IVVD $102.11
- Revenue Next Year
- ASPI $361.18
- IVVD $151.51
- P/E Ratio
- ASPI N/A
- IVVD N/A
- Revenue Growth
- ASPI 147.78
- IVVD 332.71
- 52 Week Low
- ASPI $3.65
- IVVD $0.35
- 52 Week High
- ASPI $14.49
- IVVD $3.07
- Technical
- Relative Strength Index (RSI)
- ASPI 33.45
- IVVD 56.48
- Support Level
- ASPI $5.70
- IVVD $2.38
- Resistance Level
- ASPI $8.09
- IVVD $2.70
- Average True Range (ATR)
- ASPI 0.90
- IVVD 0.24
- MACD
- ASPI -0.24
- IVVD 0.03
- Stochastic Oscillator
- ASPI 10.78
- IVVD 52.82
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.